ArticleNeuro-oncology2020

Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.

Stuart A Grossman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.